Fig. 4
From: Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro
Cell viability after treatment with masitinib or imatinib. Graphical plot of the effects of a masitinib and b imatinib on viability of MBSa1 and CoFSA cells. Cell viability was assessed using a MTS assay of MBSa1 and CoFSA treated with escalating concentrations of masitinib or imatinib after 72 h of incubation. Masitinib treated cells displayed decreased viability relative to the vehicle-treated control at 10.0, 30.0, and 100.0 μM for both MBSa1 and CoFSA (p < 0.0001). Imatinib treated cells displayed decreased viability relative to the vehicle-treated control at 30.0 and 100.0 μM for MBSa1 (p < 0.0001) and at 1.0, 3.0, 10.0, 30.0, and 100.0 μM for CoFSA (p < 0.0001). Plotted values are mean ± standard error of the mean. The calculated IC50 of masitinib for MBSa1 and CoFSA is 9.1 and 12.0 μM, respectively. The calculated IC50 of imatinib for MBSa1 and CoFSA is 33.4 and 7.9 μM, respectively